Announcements from Department of Health

Please note the following announcements from the Drug Office of Department of Health:

• FDA Requires a Warning about Guillain-Barre Syndrome (GBS) be Included in the Prescribing Information for Shingrix
• Bendamustine (Levact): increased risk of non-melanoma skin cancer and progressive multifocal encephalopathy (PML)
• Summary Safety Review - Diuretics, Including Acetazolamide - Assessing the Potential Risk of Certain Eye Disorders
• Benefits of ifosfamide solutions continue to outweigh risks EMA’s safety committee (PRAC) has concluded that the benefits of ifosfamide solutions for infusion
• The Food and Drug Administration approved revisions to the TRIUMEQ (abacavir/dolutegravir/lamivudine) and DOVATO (dolutegravir/lamivudine) labels
• Reporting of Adverse Event following Immunization (AEFI) of COVID-19 Vaccine